Search

Author/Creator Korducki, Lawrence

1. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Issue 5 (May 2015)

Authors:
Joos, Guy F.; Aumann, Joseph-Leon; Coeck, Carl; Korducki, Lawrence; Hamilton, Alan L.; Kunz, Christina; Aalbers, René
Journal:
Respiratory medicine
Issue:
Volume 109:Issue 5(2015)
Page Start:
606
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. Issue 4 (13th April 2016)

Authors:
Troosters, Thierry; Bourbeau, Jean; Maltais, François; Leidy, Nancy; Erzen, Damijan; De Sousa, Dorothy; Korducki, Lawrence; Hamilton, Alan
Journal:
BMJ open
Issue:
Volume 6:Issue 4(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. (3rd September 2015)

Authors:
McGarvey, Lorcan; Niewoehner, Dennis; Magder, Sheldon; Sachs, Paul; Tetzlaff, Kay; Hamilton, Alan; Korducki, Lawrence; Bothner, Ulrich; Vogelmeier, Claus; Koch, Andrea; Ferguson, Gary T.
Journal:
COPD
Issue:
Volume 12:Number 5(2015:Oct.)
Page Start:
484
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search